Pubblicazioni

Autori:

Schena, A; Quaglia, F M; Parisi, A; Ferrarini, I; Moioli, A; Tagliavini, E; Bernardelli, A; Visco, C

Titolo:

Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

British Journal of Haematology

ISSN Rivista:

0007-1048

N° Volume:

205

Numero o Fascicolo:

6

Intervallo pagine:

2523-2526

Parole chiave:

T-cell/histiocyte-rich large B-cell lymphoma

Breve descrizione dei contenuti:

Here, we present the results of a pilot study evaluating the efficacy of the anti-PD-1 drug pembrolizumab in seven patients with TCRLBCL (n = 3) or EBV+ DLBCL, NOS (n = 4). All patients had disease relapsed or were refractory to standard chemo-immunotherapy and had received at least two previous lines (range 2–5). Checkpoint inhibitors may represent a potential therapeutic alternative in subsets of patients who do not benefit most of CAR T-cell therapy.

Id prodotto:

145804

Handle IRIS:

11562/1162255

ultima modifica:

16 maggio 2025

Citazione bibliografica:

Schena, A; Quaglia, F M; Parisi, A; Ferrarini, I; Moioli, A; Tagliavini, E; Bernardelli, A; Visco, C, Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma «British Journal of Haematology» , vol. 205 , n. 6 , 2024 , pp. 2523-2526

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo